explore -WSS

explore

author：focus 2025-09-28 02:30:27 - browse：88559

3d rendered medically accurate illustration of the adrenal gland – biotech and pharma coverage from STAT — Adobe

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to treating patients with a rare and serious set of genetic disorders that alters their ability to produce key hormones.

In the Phase 3 study, known as CAHtalyst, 182 adults were randomly assigned to receive a placebo or crinecerfont, an oral drug Neurocrine developed to lower male sex hormones patients with the disease produce in excess. Researchers found that, compared to those on placebo, participants who took crinecerfont needed a significantly lower dose of the current standard-of-care treatment, glucocorticoids, after 24 weeks of treatment that they did at the study’s start. And about 63% of participants who took crinecerfont were able to lower their dose of glucocorticoids to levels researchers think would be safer for prolonged use, compared to 18% of those on the placebo.

Neurocine, a San Diego biotech focused on treating rare neurological and endocrine diseases, believes the drug could allow people living with congenital adrenal hyperplasia, or CAH, to avoid some of the more serious side effects of glucocorticoids by allowing them to take lower doses. Long-term use of high doses of these drugs can cause patients to gain weight and put them at risk of diabetes, heart disease, and osteoporosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

entertainment

WSS

FDA struggles to regulate food additives, sometimes for decades

UnitedHealth’s board chair also owns a personal investment firm

Why health workers in Gaza are injured or die at high rates

HHS leader on health, climate change and biopharma emissions

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Senate committee scrutinizes Medicare Advantage brokers

focus

explore

hotspot

Peter Hotez and the public health issue of online harassment

A controversial new treatment promises to make little people taller

In Memoriam: Notable people who died in 2023

Studies point to risks of excluding people with obesity from drug trials

Medicare details structure of new drug price negotiation program

2 officers injured in shooting in Orlando, police say

How one medical school became remarkably diverse

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

Jerome Adams on the need for new antivirals for Covid

Pharmacists can make shortage drugs, but at what cost?

focus

STAT Summit: Biotech founders on deal

2 officers injured in shooting in Orlando, police say

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

STAT Summit: Michael J. Fox on progress in Parkinson's research

How to ethically and practically extend health care to all

Senate committee scrutinizes Medicare Advantage brokers

Wikipedia

entertainment

focus

Wikipedia